Biggest News Aggregation in the World
📰 Planegg News

Page 19 - Planegg News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Planegg. Real-time updates on events, politics, business and more.

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution -November 29, 2023 at 10:02 am EST

EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...
United States Morgan Stanley Capital Management Dealer Services Corp Morgan Stanley Co Distribution Services Morgan Stanley

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution -November 29, 2023 at 10:03 am EST

EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...
United States Morgan Stanley Morgan Stanley Co Distribution Services Dealer Services Corp Morgan Stanley Capital Management

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution -November 29, 2023 at 10:04 am EST

EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...
United States Jp Morgan Securities Dealer Holdings Inc National Association Jpmorgan Chase Holdings Third Party

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution -November 29, 2023 at 10:05 am EST

EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...
United States Dealer Holdings Inc National Association Jpmorgan Chase Holdings Third Party Jp Morgan Securities

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution -November 29, 2023 at 10:01 am EST

EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...
United States Nb Holdings Corporation Bofaml Jersey Holdings National Association Bofa Securities Inc Notification Of Major Holdings

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution -November 27, 2023 at 10:01 am EST

EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...
United States America Corporation Nb Holdings Corporation Merrill Lynch International Distribution Services National Association

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution -November 23, 2023 at 10:01 am EST

EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...
Frankfurt Am Main Union Investment Privatfonds Gmb Notification Of Major Holdings Distribution Services Rights Announcement Voting Rights Announcement

Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

20.11.2023 - Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%)The key secondary endpoints assessing symptom reduction, ... Seite 1
Dynamic International Prognostic Scoring System Spleen Volume Morphosys Chart Orphosys Kurs Morphosys Aktie

MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

EQS-News: MorphoSys AG / Key word(s): Study resultsMorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction 20.11.2023 / 22:29 CET/CESTThe issuer is solely responsible for the content of this a...
United States San Diego Thomas Biegi Julia Neugebauer Eamonn Nolan Jean Paul Kress

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science